Nancy Martin

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

Victor W. Νitti, Stephen M. Auerbach, Nancy Martin et al. · The Journal of Urology · 2012 · 368 citations

Medicine, Pharmacology, Pharmacotherapy +17

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson et al. · European Urology · 2012 · 356 citations

Medicine, Pharmacology, Urology +14

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Sender Herschorn, Jack Barkin, David Castro‐Díaz et al. · Urology · 2013 · 246 citations

Medicine, Pharmacology, Pharmacotherapy +13

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase <scp>III</scp> studies

V. Khullar, Philip E.V. van Kerrebroeck, Sender Herschorn et al. · International Journal of Clinical Practice · 2013 · 211 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT

Kimball A. Johnson, Nancy Martin, Rossella E. Nappi et al. · The Journal of Clinical Endocrinology & Metabolism · 2023 · 193 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +13